BR112012014345A2 - peptídeos tmem22 e vacinas incluindo os mesmos - Google Patents
peptídeos tmem22 e vacinas incluindo os mesmosInfo
- Publication number
- BR112012014345A2 BR112012014345A2 BR112012014345A BR112012014345A BR112012014345A2 BR 112012014345 A2 BR112012014345 A2 BR 112012014345A2 BR 112012014345 A BR112012014345 A BR 112012014345A BR 112012014345 A BR112012014345 A BR 112012014345A BR 112012014345 A2 BR112012014345 A2 BR 112012014345A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptides
- nucleic acids
- same
- cytotoxic
- fragments
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 8
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 8
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 3
- 108020004707 nucleic acids Proteins 0.000 abstract 3
- 150000007523 nucleic acids Chemical class 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 230000006698 induction Effects 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 238000007792 addition Methods 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000002619 cancer immunotherapy Methods 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28621309P | 2009-12-14 | 2009-12-14 | |
| US28765009P | 2009-12-17 | 2009-12-17 | |
| US32638010P | 2010-04-21 | 2010-04-21 | |
| PCT/JP2010/007228 WO2011074236A1 (en) | 2009-12-14 | 2010-12-13 | Tmem22 peptides and vaccines including the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012014345A2 true BR112012014345A2 (pt) | 2017-01-10 |
Family
ID=44167006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012014345A BR112012014345A2 (pt) | 2009-12-14 | 2010-12-13 | peptídeos tmem22 e vacinas incluindo os mesmos |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US8697631B2 (enExample) |
| EP (1) | EP2513136A4 (enExample) |
| JP (1) | JP2013513549A (enExample) |
| KR (1) | KR20120104350A (enExample) |
| CN (1) | CN102770441A (enExample) |
| AU (1) | AU2010331648A1 (enExample) |
| BR (1) | BR112012014345A2 (enExample) |
| CA (1) | CA2782977A1 (enExample) |
| IL (1) | IL220146A0 (enExample) |
| MX (1) | MX2012006770A (enExample) |
| RU (1) | RU2012130015A (enExample) |
| SG (2) | SG181530A1 (enExample) |
| TW (1) | TW201136604A (enExample) |
| WO (1) | WO2011074236A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2805989A1 (en) | 2010-07-19 | 2012-01-26 | Yeda Research And Development Co. Ltd. | Peptides based on the transmembrane domain of a toll-like receptor (tlr) for treatment of tlr-mediated diseases |
| EP2766384B1 (en) * | 2011-10-10 | 2016-11-23 | Yeda Research and Development Co. Ltd. | Toll-like receptor 4 (tlr-4) agonist peptides for modulating tlr-4 mediated immune response |
| BR112015012234A2 (pt) * | 2012-12-04 | 2017-08-15 | Oncotherapy Science Inc | Peptídios sema5b e vacinas contendo os mesmos |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| EP0239102A3 (en) | 1986-03-28 | 1989-07-12 | Tsuji, Kimiyoshi | Process for the formation of human-human hybridoma |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| EP0841945B1 (en) | 1995-08-03 | 2006-03-08 | Rijksuniversiteit te Leiden | Cell derived antigen presenting vesicles |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| US6294378B1 (en) | 1996-07-26 | 2001-09-25 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| AU6765098A (en) | 1997-03-19 | 1998-10-12 | Genetics Institute Inc. | Secreted proteins and polynucleotides encoding them |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| ES2294844T3 (es) | 1998-06-25 | 2008-04-01 | Green Peptide Co., Ltd. | Peptidos antigenicos tumorales derivados de ciclofilina b. |
| CA2440773A1 (en) | 2001-03-14 | 2002-09-19 | Dakocytomation Denmark A/S | Novel mhc molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of mhc molecules |
| CA2399569A1 (en) | 2001-09-25 | 2003-03-25 | Yusuke Nakamura | Diagnostic markers and drug targets for treatment of cancer |
| GB2392158B (en) | 2002-08-21 | 2005-02-16 | Proimmune Ltd | Chimeric MHC protein and oligomer thereof |
| CN103073620B (zh) | 2002-09-12 | 2014-12-10 | 肿瘤疗法科学股份有限公司 | Kdr肽和包括该肽的疫苗 |
| CA2580412A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| WO2007013575A2 (en) | 2005-07-28 | 2007-02-01 | Oncotherapy Science, Inc. | Method for diagnosing and treating renal cell carcinoma |
| JP5276846B2 (ja) | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
| JP5984324B2 (ja) | 2005-12-01 | 2016-09-06 | メディカル プログノシス インスティテュート エー／エス | 治療反応のバイオマーカーを同定するための方法および装置、ならびに治療効果を推定するためのその使用 |
| TW201425333A (zh) | 2007-04-11 | 2014-07-01 | Oncotherapy Science Inc | 腫瘤血管內皮標誌８胜肽及包含此胜肽之疫苗 |
| TW200932260A (en) | 2007-11-28 | 2009-08-01 | Oncotherapy Science Inc | STAT3 epitope peptides |
| CA2715501A1 (en) | 2008-02-15 | 2009-09-24 | Pacific Arrow Limited | Blocking the metastasis of cancer cells and the uses of new compounds thereof |
-
2010
- 2010-12-10 TW TW099143200A patent/TW201136604A/zh unknown
- 2010-12-13 AU AU2010331648A patent/AU2010331648A1/en not_active Abandoned
- 2010-12-13 EP EP20100837268 patent/EP2513136A4/en not_active Withdrawn
- 2010-12-13 MX MX2012006770A patent/MX2012006770A/es active IP Right Grant
- 2010-12-13 JP JP2012527547A patent/JP2013513549A/ja active Pending
- 2010-12-13 SG SG2012041471A patent/SG181530A1/en unknown
- 2010-12-13 CA CA2782977A patent/CA2782977A1/en not_active Abandoned
- 2010-12-13 CN CN2010800638296A patent/CN102770441A/zh active Pending
- 2010-12-13 WO PCT/JP2010/007228 patent/WO2011074236A1/en not_active Ceased
- 2010-12-13 BR BR112012014345A patent/BR112012014345A2/pt not_active IP Right Cessation
- 2010-12-13 US US13/515,656 patent/US8697631B2/en not_active Expired - Fee Related
- 2010-12-13 RU RU2012130015/10A patent/RU2012130015A/ru not_active Application Discontinuation
- 2010-12-13 KR KR1020127018341A patent/KR20120104350A/ko not_active Withdrawn
- 2010-12-13 SG SG10201408245WA patent/SG10201408245WA/en unknown
-
2012
- 2012-06-04 IL IL220146A patent/IL220146A0/en unknown
-
2014
- 2014-03-21 US US14/221,721 patent/US20140199336A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140199336A1 (en) | 2014-07-17 |
| AU2010331648A1 (en) | 2012-06-21 |
| CA2782977A1 (en) | 2011-06-23 |
| WO2011074236A1 (en) | 2011-06-23 |
| IL220146A0 (en) | 2012-07-31 |
| SG181530A1 (en) | 2012-07-30 |
| RU2012130015A (ru) | 2014-01-27 |
| US20120308591A1 (en) | 2012-12-06 |
| EP2513136A4 (en) | 2013-06-19 |
| EP2513136A1 (en) | 2012-10-24 |
| CN102770441A (zh) | 2012-11-07 |
| TW201136604A (en) | 2011-11-01 |
| US8697631B2 (en) | 2014-04-15 |
| JP2013513549A (ja) | 2013-04-22 |
| MX2012006770A (es) | 2012-07-20 |
| KR20120104350A (ko) | 2012-09-20 |
| SG10201408245WA (en) | 2015-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ733168A (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| EA201892021A1 (ru) | Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний | |
| EA201891759A1 (ru) | Трансфицированные t-клетки и t-клеточные рецепторы для применения в иммунотерапии раковых заболеваний | |
| CR20200433A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (div. 3. 2018-74) | |
| EA202191027A3 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей | |
| EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| MX2011008763A (es) | Peptidos foxm1 y vacunas que contienen los mismos. | |
| EA202091250A2 (ru) | Новые способы иммунотерапии нескольких видов опухолей, в том числе рака желудочно-кишечного тракта и рака желудка | |
| BR112012013139A2 (pt) | oligopeptídeos imp-3 e vacinas incluindo os mesmos | |
| MX2011007963A (es) | Peptidos neil3 y vacunas que incluyen los mismos. | |
| BR112012018457A2 (pt) | peptídeos melk modificados e vacinas contendo os mesmos | |
| BR112013031056A2 (pt) | peptídeos de sema5b e vacinas incluindo os mesmos | |
| PH12014500720A1 (en) | Topk peptides and vaccines including the same | |
| BR112012025567A2 (pt) | peptídeos de cdca5 e vacinas que incluem os mesmos | |
| BR112014001363A2 (pt) | peptídeos mphosph1 e vacinas incluindo os mesmos | |
| BR112012014345A2 (pt) | peptídeos tmem22 e vacinas incluindo os mesmos | |
| EP3208334A3 (en) | Cdc45l peptides and vaccines including the same | |
| EA201390811A1 (ru) | Пептиды tomm34 и содержащие их вакцины | |
| MX2011008917A (es) | Peptidos vangl1 y vacunas que incluyen los mismos. | |
| BR112012024997A2 (pt) | peptídeos ect2 e vacinas incluindo os mesmos | |
| BR112012022641A2 (pt) | peptídeos hjurp e vacinas que incluem os mesmos | |
| BR112013009276A2 (pt) | peptídeos de c18orf54 e vacinas incluindo os mesmos | |
| BR112013009526A2 (pt) | peptídeos de wdhd1 e vacinas incluindo os mesmos | |
| PH12012501935A1 (en) | Ect2 peptides and vaccines including the same | |
| NZ746513A (en) | Novel peptides and combination of peptides for use in immunotherapy against various tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |